Navigation Links
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting

CDC), an estimated 3.9 million Americans (1.8%) have been infected with HCV, of whom 2.7 million are chronically infected. It is estimated that there are 170 million people worldwide afflicted with this disease. While currently available therapies can cure many patients, there is considerable need for the development of novel therapeutic approaches. The HCV NS3/4 protease is an attractive drug target because of its potential involvement in viral replication and suppressive effects on host response to viral infection. Inhibitors of the HCV protease, such as ITMN-191, represent a promising new class of drugs for HCV.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 in Phase 1a, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Except for the historical information contained herein, this press release contains certain forward-looking statements that involve risks and uncertainties, including without limitation the statements related to the progress, future patient enrollment in and timing of our clinical trials and announcements of results thereof. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof
'"/>




Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: InterMune Presents Research ITMN Hepatitis EASL Annual Meeting
(Date:7/24/2014)... 24, 2014  Uroplasty, Inc. (NASDAQ: UPI ... and markets innovative proprietary products to treat voiding ... 2015 first quarter ended June 30, 2014.  ... Neuromodulation System grew 19% to $4.1 million, as ... of the prior year.  Total revenue for the ...
(Date:7/24/2014)... Ohio, July 24, 2014  Mettler-Toledo International Inc. (NYSE: ... for 2014.  Provided below are the highlights: ... the quarter compared with the prior year. Reported sales ... , Net earnings per diluted share as reported ... quarter of 2013. Adjusted EPS was $2.57, an increase ...
(Date:7/24/2014)... THOUSAND OAKS, Calif. , July 24, 2014 ... will report its second quarter financial results on Tuesday, July ... The announcement will be followed by a conference call with ... call from Amgen will be Robert A. Bradway , ... senior management team. Live audio of the conference ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
... Facility, VIENNA, Va., Aug. 14 CEL-SCI CORPORATION,(Amex: ... into an agreement with a,biomedical real estate group under ... facility for its cancer drug Multikine(R). The,financial value of ... is located near Baltimore, Maryland. Once fully built out ...
... ALTO, Calif., Aug. 15 CV Therapeutics,Inc. (Nasdaq: ... developed jointly,by the American College of Cardiology Foundation ... week,s issue of Circulation, state that,"ranolazine may be ... Ranexa(R) (ranolazine extended-release tablets) is indicated for the,treatment ...
Cached Medicine Technology:CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 2CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 3CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug 4Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI) 2
(Date:7/24/2014)... July 24, 2014 The federal ... ) in the U.S. District Court, District ... for plaintiff medical information covered by the federal ... the July 16th Order, U.S. District Judge Douglas ... Fresenius Medical Care the right to receive HIPAA- ...
(Date:7/24/2014)... American Society of Association Executives (ASAE) announced its 2014 ... of the American Society of Anesthesiologists (ASA). , ... Power of A Gold Award, one of the top ... the betterment of the world through education on the ... improve anesthesia care. , ASA was also honored with ...
(Date:7/24/2014)... July 24, 2014 Pools and beaches are ... water can be dangerous, especially for small children, so ... safety. , According to the Centers for Disease Control and ... most at risk for water-related injuries and deaths. It’s important ... around water, so Amica is offering the following tips from ...
(Date:7/24/2014)... News Facts , Lexmark’s ... certification for compliance with Department of Defense (DoD) ... DoD Information Assurance Certification and Accreditation Process (DIACAP). ... the DoD as the Enterprise Clinical Imaging Archive, ... the U.S. Army Medical Materiel Agency. , DIACAP ...
(Date:7/24/2014)... July 24, 2014 A new study led ... into the interplay among bacteria, viruses and the immune ... men,s infectivity their potential to infect others ... produce large amounts of virus in their semen despite ... "compartmentalization," where different levels of the virus can be ...
Breaking Medicine News(10 mins):Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2
... Steven Reinberg HealthDay Reporter , THURSDAY, Nov. ... medications can help people with heart disease live ... according to new guidelines from the American College of ... Following the updated recommendations can also improve quality of ...
... have found important new relationships between obesity, sleep-disordered ... children. "The intricate interdependencies between BMI, ... of particular importance in children, as their brains ... Spruyt, PhD, assistant professor in the Department of ...
... Nancy Grace and her partner danced a lively rumba to Spandau ... more was going on in the legal commentator,s brain than worry ... millions of neurons were hard at work doing what they apparently ... MacManus,s movements to create a pas de deux that had the ...
... , THURSDAY, Nov. 3 (HealthDay News) -- Smokers are more ... area of their brain that processes emotions was damaged by ... people who planned to stop smoking before they had a ... than those who hadn,t thought about quitting. These findings ...
... has long been known that cancer cells use nutrients differently ... field of cancer metabolism has shed new light on the ... demonstrating that manipulation of an enzyme called PKM2 is important ... by a scientific team at Beth Israel Deaconess Medical Center ...
... to stay awake. Very bright light not only arouses us ... can make us sleepy. It,s the reason some people use ... sleep. Now researchers at UCLA have identified ... or not. Jerome Siegel, a professor of psychiatry at ...
Cached Medicine News:Health News:Rx for Heart Patients: Healthier Living, Medication 2Health News:Rx for Heart Patients: Healthier Living, Medication 3Health News:Body weight, sleep-disordered breathing and cognition linked in children 2Health News:It takes two: Brains come wired for cooperation, neuroscientist asserts 2Health News:Some Smokers More Likely to Quit After Stroke Than Others 2Health News:Study identifies an expanded role for PKM2 in helping cancer cells survive 2Health News:Study identifies an expanded role for PKM2 in helping cancer cells survive 3Health News:UCLA researchers identify brain cells responsible for keeping us awake 2
New!...
... Electrical I/A unit for planned ... aspiration (foot control). Independent irrigation, suction, ... allows the surgeon to control all ... all functions simultaneously. Preset and actual ...
... Anterior and Posterior segment surgeries Vitrectomy-Lensectomy ... Ventury or Peristaltic Linear Aspiration. Interchangeable ... specific cutting action. Easy to read ... Cutting speed-variable from 1- 600 cuts ...
...
Medicine Products: